Skip to main content
. Author manuscript; available in PMC: 2017 Aug 11.
Published in final edited form as: Cancer Lett. 2016 Jun 17;380(1):39–46. doi: 10.1016/j.canlet.2016.06.013

Fig. 4.

Fig. 4

Expression of D2HGDH-GAL3ST2 in prostate cell lines and clinical samples. A. qRT-PCR measuring the expression of D2HGDH-GAL3ST2 in prostate benign and cancer cell lines. The expression of the fusion was normalized against internal control, GAPDH. The relative level was then set to 1.0 in LNCaP cells. B. Expression of D2HGDH-GAL3ST2 in frozen prostate biopsies by RT-PCR, followed by gel-electrophoresis. C. RNA expression of D2HGDH-GAL3ST2 in HPRT103 TissueScan array from OriGene. N1–N9, normal; T1–T18, stage II; T19–T37, stage III; T38–T39, stage IV. D. RNA expression of D2HGDH-GAL3ST2 in HPRT102 prostate clinical samples purchased from OriGene. N1–N8, normal; T1–T22, stage II; T23–T33, stage III; T34–T35, stage IV; T36–T40 unknown stage; NC is the H2O control.